Blue Star has scheduled two group meetings with analysts and institutional investors on September 10 and September 16, 2026. The engagements are part of the company’s investor relations calendar for the quarter.

Meeting details

The company announced the schedule pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Both meetings are in-person group interactions.

The schedule is subject to change. The intimation was issued on September 4, 2026, by Rajesh Parte, Company Secretary & Compliance Officer.

Blue Star Limited has completed the slump sale of its MedTech business to Cyrix Healthcare Private Limited effective September 1, 2026. The transaction involves the transfer of the medical diagnostic equipment and services division from wholly owned subsidiary Blue Star Engineering & Electronics Limited.

The deal consideration is capped at ₹40 crore, payable in tranches subject to adjustments under the Business Transfer Agreement (BTA). The final tranche is scheduled for payment by March 31, 2027. The BTA was originally executed on August 14, 2026.

Transaction Details

The MedTech division operated as a going concern within Blue Star E&E. The sale is structured outside the Scheme of Arrangement, meaning Regulation 37A of the SEBI Listing Regulations does not apply. The company confirmed that the transaction does not constitute a related-party transaction, as Cyrix is not part of the promoter group.

Financial Context

For the financial year ended March 31, 2026, the MedTech division generated total income of ₹42.13 crore. This figure represented approximately 0.33% of the company’s consolidated income from operations for the year.

The net worth of the division stood at approximately ₹7.11 crore as on March 31, 2026, constituting around 0.21% of the company’s total net worth. The company stated that the business transfer aims to allow focus on strategic priorities.

What the Numbers Show

The consideration of up to ₹40 crore represents a significant premium over the division’s reported net worth of ₹7.11 crore. This valuation multiple suggests the buyer is pricing in future cash flows or strategic synergies rather than just book value. However, the revenue contribution of 0.33% indicates the unit was marginal to the parent’s overall top line, aligning with the stated rationale of focusing on core strategic areas.